CLDN18.2 expression
|
Esophageal Adenocarcinoma
|
CLDN18.2 expression
|
Esophageal Adenocarcinoma
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
CLDN18.2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
CLDN18.2 expression
|
Gastroesophageal Junction Adenocarcinoma
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
CLDN18.2 expression
|
Gastric Adenocarcinoma
|
CLDN18.2 expression
|
Gastric Adenocarcinoma
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
IMAB362 Sensitive: C2 – Inclusion Criteria
|
CLDN18.2 expression
|
Gastric Cancer
|
CLDN18.2 expression
|
Gastric Cancer
|
Q-1802 Sensitive: C3 – Early Trials
|
Q-1802 Sensitive: C3 – Early Trials
|
CLDN18.2 expression
|
Pancreatic Cancer
|
CLDN18.2 expression
|
Pancreatic Cancer
|
ZL-1211 Sensitive: D – Preclinical
|
ZL-1211 Sensitive: D – Preclinical
|
CLDN18.2 expression
|
Gastric Cancer
|
CLDN18.2 expression
|
Gastric Cancer
|
ZL-1211 Sensitive: D – Preclinical
|
ZL-1211 Sensitive: D – Preclinical
|
CLDN18.2 expression
|
Solid Tumor
|
CLDN18.2 expression
|
Solid Tumor
|
TJ-CD4B Sensitive: D – Preclinical
|
TJ-CD4B Sensitive: D – Preclinical
|